PMID- 17484804
OWN - NLM
STAT- MEDLINE
DCOM- 20070703
LR  - 20171116
IS  - 1672-7681 (Print)
IS  - 1672-7681 (Linking)
VI  - 4
IP  - 2
DP  - 2007 Apr
TI  - Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 
      leading to induction of efficient cytotoxic T cell responses and antitumor 
      immunity.
PG  - 105-11
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) for the 
      initiation of antigen (Ag)-specific immune responses. In most studies, mature DCs 
      are generated from bone marrow cells or peripheral monocytes; in either case, the 
      harvested cells are then cultured in medium containing recombinant GM-CSF, IL-4 
      and TNF-alpha for 7-10 days and stimulated with lipopolysaccharide (LPS). 
      However, this approach is time-consuming and expensive. There is another less 
      cost approach of using immobilized DC cell lines, which can easily grow in the 
      medium. A disadvantage with the immobilized DC cell lines, however, is that they 
      are immature DCs and lack expression of MHC class II and costimulatory CD40 and 
      CD80 molecules. This, therefore, limits their capacity for inducing efficient 
      antitumor immunity. In the current study, we investigated the possible efficacy 
      of various stimuli (IL-1beta,IFN-gamma, TNF-alpha, CpG and LPS) in converting the 
      immature dendritic cell line DC2.4 to mature DCs. Our findings were quite 
      interesting since we demonstrated for the first time that IFN-gamma was able to 
      stimulate the maturation of DC2.4 cells. The IFN-gamma-activated ovalbumin 
      (OVA)-pulsed DC2.4 cells have capacity to upregulate MHC class II, CD40, CD80 and 
      CCR7, and to more efficiently stimulate in vitro and in vivo OVA-specific CD8+ T 
      cell responses and antitumor immunity. Therefore, IFN-gamma-activated immortal 
      DC2.4 cells may prove to be useful in the study of DC biology and antitumor 
      immunity.
FAU - He, Tianpei
AU  - He T
AD  - Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department 
      of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada.
FAU - Tang, Chaoke
AU  - Tang C
FAU - Xu, Shulin
AU  - Xu S
FAU - Moyana, Terence
AU  - Moyana T
FAU - Xiang, Jim
AU  - Xiang J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Cell Mol Immunol
JT  - Cellular & molecular immunology
JID - 101242872
RN  - 0 (B7-1 Antigen)
RN  - 0 (CD40 Antigens)
RN  - 0 (Ccr7 protein, mouse)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Receptors, Chemokine)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - B7-1 Antigen/metabolism
MH  - CD40 Antigens/metabolism
MH  - Cell Communication/*immunology
MH  - Cell Differentiation/*immunology
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Dendritic Cells/*immunology/metabolism/transplantation
MH  - Female
MH  - Histocompatibility Antigens Class II/metabolism
MH  - Immunotherapy, Adoptive/*methods
MH  - Interferon-gamma/*immunology
MH  - Lymphocyte Activation
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Neoplasms, Experimental/immunology/metabolism/pathology/*therapy
MH  - Ovalbumin/immunology
MH  - Phenotype
MH  - Receptors, CCR7
MH  - Receptors, Chemokine/metabolism
MH  - Signal Transduction/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism/transplantation
EDAT- 2007/05/09 09:00
MHDA- 2007/07/04 09:00
CRDT- 2007/05/09 09:00
PHST- 2007/05/09 09:00 [pubmed]
PHST- 2007/07/04 09:00 [medline]
PHST- 2007/05/09 09:00 [entrez]
PST - ppublish
SO  - Cell Mol Immunol. 2007 Apr;4(2):105-11.